Translational Oncology, II. Med Clinics Hematology and Oncology, 86156, Augsburg, Germany.
Institute of Molecular Oncology, Member of the German Center for Lung Research (DZL), Philipps University, 35043 Marburg, Germany.
Trends Pharmacol Sci. 2024 Jun;45(6):475-477. doi: 10.1016/j.tips.2024.04.011. Epub 2024 May 10.
Cancer-targeted therapies that inhibit oncogenic signaling often lead to resistance and recurrence. In a recent study, Dias et al. propose activating oncogenic pathways and inducing replication stress, resulting in cell death and tumor-suppressive mechanisms in colorectal cancer (CRC). This approach could spark a new wave of target discovery, and drug development and repurposing against cancer.
针对抑制致癌信号的癌症靶向治疗常常导致耐药性和复发。在最近的一项研究中, Dias 等人提出激活致癌途径并诱导复制应激,导致结直肠癌(CRC)中的细胞死亡和肿瘤抑制机制。这种方法可能引发针对癌症的新一波靶标发现、药物研发和再利用。